ArticleCurrent microbiology2026
Deletion of MSMEG_3118, an ABC Transporter Family Protein in Mycobacterium smegmatis Alters Lipids Profile and Drug Susceptibility.
Article in Current microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multidrug resistant tuberculosis (MDR-TB) poses a serious global health concern. The development of drug-resistant mycobacterial strains is likely influenced by efflux transporters. In this study we created a deletion mutant of MSMEG_3118, a hypothetical efflux pump protein in Mycobacterium smegmatis, and characterized the mutant. It is shown that MSMEG_3118 acts as an efflux pump, and its deletion results in enhanced accumulation of the ethidium bromide. The MSMEG_3118 deletion mutant exhibited noticeable changes in colony morphology, slower growth rates, and reduced biofilm formation, indicating a larger role of this protein in mycobacterial physiology. Lipids profile showed elevated levels of menaquinone in the mutant. Interestingly, the mutant showed increased sensitivity to clofazimine and the proton motive force inhibitor CCCP but rendered higher resistance to several first- and second-line anti-tubercular drugs, such as rifampicin, isoniazid, streptomycin, vancomycin and erythromycin. All the changes in the mutant phenotypes were duly restored in the complemented mutant strain, suggesting a larger role of this protein in addition to an efflux pump transporter. Summarily, these results highlight a complex regulatory network that contributes to the multidrug resistance in mycobacteria.
Indexed as
Identifiers
42821104What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.